Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

D. Wolchok, Jedd; Chiarion-Sileni, Vanna; Gonzalez, Rene; Grob, Jean-Jacques; Rutkowski, Piotr; D. Lao, Christopher; Lance Cowey, C.; Schadendorf, Dirk; Wagstaff, John; Dummer, Reinhard; Francesco Ferrucci, Pier; Smylie, Michael; O. Butler, Marcus; Hill, Andrew; Márquez-Rodas, Ivan; B. A. G. Haanen, John; Guidoboni, Massimo; Maio, Michele; Schöffski, Patrick; S. Carlino, Matteo; Lebbé, Céleste; McArthur, Grant; A. Ascierto, Paolo; A. Daniels, Gregory; V. Long, Georgina; Bas, Tuba; Ritchings, Corey; Larkin, James; Stephen Hodi, F.

doi:10.1200/jco.21.02229

Public

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Published in Journal of Clinical Oncology • Nov 24, 2021

Authors:

Jedd D. Wolchok

Vanna Chiarion-Sileni

Rene Gonzalez

Abstract

PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes. PATIENTS AND METHODS: Patients with previously untreated unresectable stage...

Subject

Nivolumab

Ipilimumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!